MX2021000331A - Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada). - Google Patents
Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada).Info
- Publication number
- MX2021000331A MX2021000331A MX2021000331A MX2021000331A MX2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A
- Authority
- MX
- Mexico
- Prior art keywords
- ada
- immunoassay
- interference
- mitigate
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696016P | 2018-07-10 | 2018-07-10 | |
| PCT/US2019/040950 WO2020014194A1 (en) | 2018-07-10 | 2019-07-09 | Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000331A true MX2021000331A (es) | 2021-03-25 |
Family
ID=67544324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000331A MX2021000331A (es) | 2018-07-10 | 2019-07-09 | Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada). |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12055551B2 (enExample) |
| EP (1) | EP3821255B1 (enExample) |
| JP (3) | JP7493459B2 (enExample) |
| KR (1) | KR102754704B1 (enExample) |
| CN (1) | CN112384808B (enExample) |
| AU (1) | AU2019301614B2 (enExample) |
| BR (1) | BR112020022912A2 (enExample) |
| EA (1) | EA202190237A1 (enExample) |
| ES (1) | ES2993989T3 (enExample) |
| IL (1) | IL277888B2 (enExample) |
| MA (1) | MA53130A (enExample) |
| MX (1) | MX2021000331A (enExample) |
| MY (1) | MY207418A (enExample) |
| SG (1) | SG11202011283TA (enExample) |
| WO (1) | WO2020014194A1 (enExample) |
| ZA (1) | ZA202006409B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
| CN114264814B (zh) * | 2021-12-30 | 2025-03-14 | 苏州和锐生物科技有限公司 | 一种pd-1生物制剂的抗体检测试剂盒及制备方法 |
| CN114324894A (zh) * | 2021-12-31 | 2022-04-12 | 军科正源（北京）药物研究有限责任公司 | 一种检测贝伐珠单抗抗药性抗体的新型分析方法 |
| CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
| WO2023204378A1 (ko) * | 2022-04-19 | 2023-10-26 | 의료법인 성광의료재단 | 혈액 내 항-약물항체 농도 측정을 통한 생물학적 약물에 대한 치료 반응성 예측 방법 |
| AU2023329315A1 (en) * | 2022-08-24 | 2025-01-16 | Amgen Inc. | Anti-drug antibody assays |
| CN115586337A (zh) * | 2022-09-14 | 2023-01-10 | 杭州赛基生物科技有限公司 | 检测肿瘤伴随诊断相关因子的试剂盒及其制备方法 |
| US20250383363A1 (en) * | 2022-09-23 | 2025-12-18 | Merck Sharp & Dohme Llc | Neutralization antibody assay method |
| CN115575468B (zh) * | 2022-09-30 | 2025-08-26 | 华润生物医药有限公司 | 一种检测抗重组人GLP-1-Fc融合蛋白抗体的方法 |
| CN115856322A (zh) * | 2022-12-23 | 2023-03-28 | 同昕生物技术（北京）有限公司 | 用于抗奥马株单抗药物抗体检测的试剂及其应用 |
| CN117805382B (zh) * | 2024-02-28 | 2024-05-03 | 军科正源（北京）药物研究有限责任公司 | 检测抗利妥昔单抗中和抗体的方法 |
| WO2025224166A1 (en) * | 2024-04-23 | 2025-10-30 | F. Hoffmann-La Roche Ag | Anti-drug antibody assays |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856469A (en) | 1973-01-02 | 1974-12-24 | Syva Corp | Interferant removal from amphetamine immunoassay |
| JPS55145690A (en) | 1979-05-04 | 1980-11-13 | Toyama Chem Co Ltd | Novel penicillin and cephalosporin, and its salt |
| JPS6454356A (en) * | 1987-08-26 | 1989-03-01 | Meidensha Electric Mfg Co Ltd | Method for suppressing non-specific adsorption of antibody to solid phase antigen |
| JPH02138872A (ja) * | 1988-11-18 | 1990-05-28 | Asahi Chem Ind Co Ltd | 癌関連物質のための免疫測定方法 |
| JPWO2005031353A1 (ja) | 2003-09-26 | 2006-12-07 | 松下電器産業株式会社 | 免疫反応測定方法、ならびにそれに用いる試薬、キット、及び光学セル |
| CA2686206A1 (en) * | 2007-05-07 | 2008-11-13 | Wyeth | Elimination of interference in immunoassays caused by anti-carbohydrate antibodies |
| WO2009022001A1 (en) | 2007-08-16 | 2009-02-19 | Novartis Ag | Improvement of drug tolerance in immunogenicity testing |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| BR112015032960B1 (pt) * | 2013-07-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro |
| WO2015123315A1 (en) * | 2014-02-11 | 2015-08-20 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| WO2017096262A1 (en) * | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| US20190145985A1 (en) | 2017-11-10 | 2019-05-16 | BioAgilytix Labs, LLC | Method for eliminating target interference |
| MX2020004921A (es) | 2017-11-29 | 2020-08-27 | Hoffmann La Roche | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo. |
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
-
2019
- 2019-07-09 AU AU2019301614A patent/AU2019301614B2/en active Active
- 2019-07-09 JP JP2020564556A patent/JP7493459B2/ja active Active
- 2019-07-09 MY MYPI2020005155A patent/MY207418A/en unknown
- 2019-07-09 EA EA202190237A patent/EA202190237A1/ru unknown
- 2019-07-09 MA MA053130A patent/MA53130A/fr unknown
- 2019-07-09 IL IL277888A patent/IL277888B2/en unknown
- 2019-07-09 EP EP19749872.8A patent/EP3821255B1/en active Active
- 2019-07-09 WO PCT/US2019/040950 patent/WO2020014194A1/en not_active Ceased
- 2019-07-09 SG SG11202011283TA patent/SG11202011283TA/en unknown
- 2019-07-09 ES ES19749872T patent/ES2993989T3/es active Active
- 2019-07-09 KR KR1020207033049A patent/KR102754704B1/ko active Active
- 2019-07-09 US US16/506,379 patent/US12055551B2/en active Active
- 2019-07-09 MX MX2021000331A patent/MX2021000331A/es unknown
- 2019-07-09 BR BR112020022912-1A patent/BR112020022912A2/pt unknown
- 2019-07-09 CN CN201980046236.XA patent/CN112384808B/zh active Active
-
2020
- 2020-10-15 ZA ZA2020/06409A patent/ZA202006409B/en unknown
-
2024
- 2024-02-20 JP JP2024023599A patent/JP2024045646A/ja active Pending
- 2024-07-03 US US18/763,265 patent/US20240353423A1/en active Pending
-
2025
- 2025-10-23 JP JP2025179025A patent/JP2026012856A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112384808B (zh) | 2024-10-11 |
| AU2019301614A1 (en) | 2020-10-22 |
| KR102754704B1 (ko) | 2025-01-20 |
| ZA202006409B (en) | 2025-07-30 |
| WO2020014194A1 (en) | 2020-01-16 |
| JP7493459B2 (ja) | 2024-05-31 |
| EP3821255A1 (en) | 2021-05-19 |
| US20200018770A1 (en) | 2020-01-16 |
| BR112020022912A2 (pt) | 2021-02-23 |
| US12055551B2 (en) | 2024-08-06 |
| IL277888A (en) | 2020-11-30 |
| KR20210031854A (ko) | 2021-03-23 |
| CA3098206A1 (en) | 2020-01-16 |
| JP2021531448A (ja) | 2021-11-18 |
| US20240353423A1 (en) | 2024-10-24 |
| AU2019301614B2 (en) | 2025-11-20 |
| SG11202011283TA (en) | 2020-12-30 |
| CN112384808A (zh) | 2021-02-19 |
| IL277888B1 (en) | 2024-12-01 |
| ES2993989T3 (en) | 2025-01-15 |
| EA202190237A1 (ru) | 2021-04-15 |
| JP2026012856A (ja) | 2026-01-27 |
| EP3821255B1 (en) | 2024-08-28 |
| MY207418A (en) | 2025-02-26 |
| IL277888B2 (en) | 2025-04-01 |
| JP2024045646A (ja) | 2024-04-02 |
| MA53130A (fr) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000331A (es) | Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada). | |
| MX2024013186A (es) | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| PE20191708A1 (es) | ANTICUERPOS DE UNION A VISTA A pH ACIDO | |
| SA519402365B1 (ar) | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية التائية | |
| PE20221282A1 (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
| BR112013021350A2 (pt) | anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes | |
| BRPI0919853B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r) e seus usos | |
| BR112022009602A2 (pt) | Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| BR112022005404A2 (pt) | Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap) | |
| BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april | |
| BR112018007842A2 (pt) | imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk) | |
| PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
| BR112021011351A2 (pt) | Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica | |
| BR112022000481A2 (pt) | Conjuntos de anticorpos e de ácidos nucleicos, vetor de expressão, célula hospedeira e métodos de pré-direcionamento de radioimunoterapia e de direcionamento de um radioisótopo | |
| ECSP22056627A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| MX2008000282A (es) | Anticuerpos monoclonales, lineas celulares de hibridomas, metodos y kits para la deteccion de fitasa. | |
| MX2017005156A (es) | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. | |
| BR112022003471A2 (pt) | Sistema receptor de antígeno quimérico e usos do mesmo | |
| WO2018226098A3 (en) | METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF | |
| BR112018075901A2 (pt) | anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro | |
| EP4171604A4 (en) | ANTI-SARS-COV-2 SERUM ANTIBODY PROFILING | |
| MX2022014580A (es) | Ensayo de multiplex doble para multiples isotipos de inmunoglobulina. | |
| MY194325A (en) | Test object detection method, and immunoassay instrument and monoclonal antibody for same |